-
Add to Cart The item has been addedF127011-25mgForetinib (GSK1363089) (C09-0886-232)
Price: $378.58List Price: $420.65Foretinib (GSK1363089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM. Less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFRAn ATP-competitive -
Add to Cart The item has been addedF127011-5mgForetinib (GSK1363089) (C09-0886-233)
Price: $112.33List Price: $124.81Foretinib (GSK1363089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM. Less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFRAn ATP-competitive -
Add to Cart The item has been addedF610384-10mgFosifidancitinib (C09-1539-620)
Price: $595.82List Price: $662.03Fosifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Fociatinib is used in studies of allergies, asthma and autoimmune diseases. -
Add to Cart The item has been addedF610384-1mgFosifidancitinib (C09-1539-621)
Price: $182.90List Price: $203.22Fosifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Fociatinib is used in studies of allergies, asthma and autoimmune diseases. -
Add to Cart The item has been addedF610384-50mgFosifidancitinib (C09-1539-622)
Price: $1,337.72List Price: $1,486.35Fosifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Fociatinib is used in studies of allergies, asthma and autoimmune diseases. -
Add to Cart The item has been addedA7461-10 mgFound in Dipsacus asper. It decreases levels of oxidative enzymes, improves left ventricle systolic pressure and left ventricle end-diastolic pressure, and suppresses expression of pro-inflammatory cytokines IL-6 and TNF-a. (C08-0488-643)
Price: $222.51List Price: $247.23AS-703026 is an inhibitor of MEK1/2 that exhibits anticancer chemotherapeutic activity. In vitro, AS-703026 inhibits proliferation of melanoma cells. -
Add to Cart The item has been addedA7461-25 mgFound in Dipsacus asper. It decreases levels of oxidative enzymes, improves left ventricle systolic pressure and left ventricle end-diastolic pressure, and suppresses expression of pro-inflammatory cytokines IL-6 and TNF-a. (C08-0489-015)
Price: $376.45List Price: $418.28AS-703026 is an inhibitor of MEK1/2 that exhibits anticancer chemotherapeutic activity. In vitro, AS-703026 inhibits proliferation of melanoma cells. -
Add to Cart The item has been addedA7461-100 mgFound in Dipsacus asper. It decreases levels of oxidative enzymes, improves left ventricle systolic pressure and left ventricle end-diastolic pressure, and suppresses expression of pro-inflammatory cytokines IL-6 and TNF-a. (C08-0489-663)
Price: $1,181.78List Price: $1,313.09AS-703026 is an inhibitor of MEK1/2 that exhibits anticancer chemotherapeutic activity. In vitro, AS-703026 inhibits proliferation of melanoma cells. -
Add to Cart The item has been addedrp174037-500μgFPRL1-inhibitor protein (C09-1187-684)
Price: $1,623.53List Price: $1,803.92FPRL1-inhibitor protein. -
Add to Cart The item has been addedAb182827-100μgFrovocimab (anti-PCSK9) (C09-1612-324)
Price: $190.21List Price: $211.35Frovocimab (anti-PCSK9) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab (anti-PCSK9) inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact -
Add to Cart The item has been addedAb182827-10mgFrovocimab (anti-PCSK9) (C09-1612-325)
Price: $2,618.06List Price: $2,908.96Frovocimab (anti-PCSK9) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab (anti-PCSK9) inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact -
Add to Cart The item has been addedAb182827-1mgFrovocimab (anti-PCSK9) (C09-1612-326)
Price: $632.31List Price: $702.57Frovocimab (anti-PCSK9) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab (anti-PCSK9) inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact
